Skip to main content
Home

Main navigation

  • Home
  • News
  • About HIV
  • About us
  • Donate
Search
Donate now

With Gift Aid, your generous donation of £10 would be worth £12.50 at no extra cost to you.

I am a UK taxpayer and I understand that if I pay less Income and /or Capital Gains Tax than the amount of Gift Aid claimed on all my donations in the relevant tax year, it is my responsibility to pay any difference.

In our 35th year we’re asking people to donate £35 – that’s just £1 for every year we’ve been providing life-changing information. Any donation you make helps us continue our work towards a world where HIV is no longer a threat to health or happiness.

  • £5 allows us to reach millions of people globally with accurate and reliable resources about HIV prevention and treatment.
  • £10 helps us produce news and bulletins on the latest developments in HIV for healthcare staff around the world.
  • £35 means we can empower more people living with HIV to challenge stigma with our information workshops, videos and broadcasts.
Conferences

International Liver Congress – 2017

The International Liver Congress 2017 (ILC 2017), the annual meeting of the European Association for the Study of the Liver (EASL), was held in Amsterdam, the Netherlands, from 19-23 April 2017.
Hepatitis B

EASL releases updated hepatitis B guidelines at International Liver Congress

26 April 2017
Hepatitis C treatment

Generic hepatitis C drugs continue to produce high cure rates

24 April 2017
Hepatitis B

Besifovir and tenofovir exalidex look promising as new hepatitis B drugs

8 May 2017
New & experimental hepatitis C treatment

Triple combination cures most hepatitis C patients with prior DAA treatment failure

28 April 2017
Hepatitis B

Switching to TAF for hepatitis B improves kidney function and bone loss

26 April 2017
New & experimental hepatitis C treatment

AbbVie combination cures 95% of genotype 3 hepatitis C

21 April 2017
New & experimental hepatitis C treatment

New AbbVie hepatitis C combination cures 99% of people with cirrhosis

21 April 2017
Hepatitis C treatment

Direct-acting antivirals for hepatitis C not linked to higher liver cancer risk in most studies

21 April 2017
Hepatitis C treatment

European HCV treatment access survey shows big variations in eligibility

20 April 2017
Hepatitis C treatment

Curing hepatitis C reduces cardiovascular risk

20 April 2017
Sign up for our email bulletins.
Sign up

Editors’ picks from other sources

Hepatitis B

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

Hepatitis B virus (HBV) infection remains a global public health problem with changing epidemiology due to several factors including vaccination policies and migration. This Clinical Practice Guideline presents updated recommendations for the optimal management of HBV infection.
EASL
24 Apr 17
Elimination of hepatitis C

New hepatitis data highlight need for urgent global response

New WHO data reveal that an estimated 325 million people worldwide are living with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. The WHO Global hepatitis report, 2017 indicates that the large majority of these people lack access to life-saving testing and treatment. As a result, millions of people are at risk of a slow progression to chronic liver disease, cancer, and death.
World Health Organization
21 Apr 17
Access to healthcare

The Medicines Patent Pool and Pharco Pharmaceuticals Sign Licence for Promising Hepatitis C Drug Candidate Ravidasvir

The Medicines Patent Pool (MPP) announced a new licence and technology transfer agreement with Egyptian company Pharco Pharmaceuticals for ravidasvir (RAV), an investigational direct-acting antiviral (DAA) with the potential of working across all six major hepatitis C genotypes. The agreement, signed on the sidelines of the International Liver Congress in Amsterdam, will enable competitive supply of RAV in low- and middle-income countries (LMICs) including high prevalence nations Russia, Ukraine, Egypt and Iran.
Medicines Patent Pool
21 Apr 17
Hepatitis C symptoms & diagnosis

Long-term antibiotic prophylaxis reduces mortality in people with advanced liver disease

A multicenter, randomized, controlled study presented today found that long-term oral antibiotic therapy with norfloxacin improved the prognosis of people with life-threatening advanced liver disease. The study, presented at The International Liver Congress™ 2017 in Amsterdam, The Netherlands, showed that norfloxacin administration for six months was associated with a reduced risk of death and infection at six months in patients with Child-Pugh class C cirrhosis, a very severe and advanced stage of liver disease.
EASL press release
20 Apr 17
More editors' picks

About us

Our information is intended to support, rather than replace, consultation with a healthcare professional.

Talk to your doctor or another member of your healthcare team for advice tailored to your situation.

Connect with us

  • Twitter
  • Facebook
  • YouTube
  • Instagram

Links

Show — Links Hide — Links
  • Contact us
  • THT Direct Helpline
  • Subscribe to email bulletins

 

aidsmap (previously known as NAM aidsmap) is now hosted by Terrence Higgins Trust, an HIV charity based in the United Kingdom.

 

Copyright 2025 © Terrence Higgins Trust is a registered charity in England and Wales (reg. no. 288527) Company reg. no. 1778149 and a registered charity in Scotland (reg. no. SC039986). Registered office: 437 & 439 Caledonian Road, London, N7 9BG.

Footer menu

Show — Footer menu Hide — Footer menu
  • Accessibility
  • Compliment, complaint or concern
  • Our information
  • Privacy & cookies
  • Terms of use
  • Terrence Higgins Trust